cyrilzakka/clinical-trials huggingface dataset:
Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics.


Eligibility Criteria:
Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. Patients aged ≥12 years
2. Patients with confirmed diagnosis of moderate-to-severe AD as assessed by the physician
3. Patients for whom the physician's decision has been made to newly prescribe abrocitinib in usual clinical practice conditions
4. Evidence of a personally signed and dated informed consent/assent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study

Exclusion Criteria:

Patients meeting any of the following criteria will not be included in the study:

1. Any prior use of abrocitinib
2. Simultaneous participation in a study that includes administration of any investigational drug or procedure
"Efficacy of Intermittent Enteral Nutrition Versus Continuous Administration in Intensive Care"

The goal of this clinical trial is to Determine efficacy of intermittent enteral nutrition vs continuous enteral nutrition in adults patients with a nasogastric tube in a intensive care unit.

The main question\[s\] it aims to answer are:

* Reduction of gastrointestinal and respiratory complications
* Evaluate the achievement of the caloric objective Informed consent will be requested from participants who meet the inclusion criteria.

The participants will be randomized into two groups: control group (continuous enteral nutrition) or experimental group (intermittent enteral nutrition) Researchers will compare intermittent enteral nutrition vs continuous to see if there is a reduction in gastrointestinal and respiratory complications.


Eligibility Criteria:
Inclusion Criteria:

* Patients admitted to ICU of University General Hospital of Albacete
* Need for enteral nutrition by nasogastric tube in the first 48 hours
* Signed informed consent

Exclusion Criteria:

* Insulin dependent diabetic patients
* Abdominal surgery
* Dire prognosis
Peritoneal Cavity Conditioning During Open Surgery.

Given the observations in animal models and the available data in the human our hypothesis is that peritoneal cavity conditioning (carbon dioxide with 4% of oxygen and 10% of N2O, 100% humidification at 32°C,) during open surgery, will result in an important decrease in postoperative peritoneal inflammation, postoperative pain, and will restore bowel transit faster.

Aim of the Trial :

RCT demonstrating that peritoneal cavity conditioning during open surgery will result in a less postoperative inflammation, less postoperative pain, and shorter time to flatus and transit.

Eligibility Criteria:
Inclusion criteria :

* patients will be stratified and randomised according to the type of surgery
* total laparoscopic hysterectomy,
* promontofixation
* cholecystectomy

Exclusion criteria :

* Any pre-existing condition increasing the risk of surgery such as age, pre-existing conditions as clotting disorders, heart or lung impairment etc.
* Not signed informed consent
* known allergic reaction to Sprayshield, Intercoat of hyalobarrier gel ® or - any bowel lesion requiring a single or double layer suture. (given that for none of the any anti-adhesion barriers safety has been proven following bowel lesions and suture)
* Any condition that might interfere with inflammatory parameters or pre-existing such as ,pregnancy, immunodeficiency, chronic inflammatory disease as Crohn's disease, chronic pain conditions as (peripheral neuropathy, pathology of the vertebral column and osteo-articular disease, any condition causing acute pain e.g. trauma.
Assessment of the Immunization Levels Against Sars-Cov2 Virus in Subjects Who Have Received EU-approved COVID-19 Vaccines

Patients who voluntarily visit vaccination centers in Greece against COVID-19 are recruited and their immunization levels against Sars-Cov2 are assesed by measurement of the levels of serum antibodies against Sars-cov-2 before vaccination and in time intervals up to 6-9 months post-vaccination (indicatively 0-1-3-6-9 months post-vaccination).


Eligibility Criteria:
Inclusion Criteria:

* Subjects who voluntarily receive COVID-19 vaccination

Exclusion Criteria:

* Patients who do not complete their vaccination
* Patients who do not provide info on their health status
Noninvasive Assessment of Tissue Perfusion Status in Critically Ill Pediatric Patients

Investigators are conducting research about oxygen levels in the body and whether it is possible to use a device to measure oxygen in the body's tissues noninvasively, without blood draws or a catheter (a plastic tube placed in a vein). Investigators would like to know how this device compares to standard measurements using blood from a catheter. This may help treat patients who may not be getting enough oxygen to their body.

Investigators will enroll patients in the pediatric intensive care unit who have an indwelling catheter that allows measurement of central venous oxygen saturation. Measurements of central venous oxygen saturation using blood oximetry will be compared with measures of tissue oxygenation at the buccal mucosa using a Raman spectroscopy tissue oximeter. Investigators will also measure the status of the sublingual microcirculation utilizing sidestream dark field microscopy. Basic demographic and clinical variables such as ongoing vasoactive infusions, mechanical ventilation, and laboratory data will also be collected.

Eligibility Criteria:
Inclusion Criteria:

* Patients admitted to the Pediatric Intensive Care Unit (PICU) or Pediatric Cardiothoracic Unit (PCTU)
* Age \>30 days and \<18 years -patients with a "high" central venous line (ie internal jugular, subclavian, peripherally inserted central catheter, broviac, port) capable of blood draw and with central venous catheter tip in the superior vena cava

Exclusion Criteria:

* Age \<30 days or \>18 years
* Known pregnancy or subsequently discovered pregnancy after admission
* Uncorrected cyanotic congenital heart disease

Relative Exclusion Criteria:

* Oral trauma preventing placement of Raman StO2 oximeter probe or microcirculation video device
* Upper extremity trauma preventing placement of BEAM device
Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer

The main purpose of this study is to evaluate the acceptance by patients with metastatic pancreas cancer of integrating palliative care with usual cancer treatment. Palliative care intervention will involve use of pancreas cancer-specific decision aides (iPC3)about prognosis, treatment choices, and advance care planning for patients facing a treatment decision as well as symptom assessments. We hypothesize that palliative care consultations with iPC3 will be accepted, symptoms can be diminished, information can be received in a way that improves choices, and that the quality of care can be improved.

* Each patient undergoing treatment at Johns Hopkins for metastatic pancreas cancer will receive palliative care support during their course to include: palliative care consultation early in their treatment course; patient decision aids that give survival, treatment benefits and risks; suggestions to complete such tasks as advance directives, durable power of medical attorney, wills, family and spiritual reviews as recommend by the American Society of Clinical Oncology; and when indicated, transition to hospice.
* Patient will have an iPad for their visit, and a corresponding website to print information.
* Each patient will assess their distress with the Distress thermometer; symptoms with the Condensed Memorial Symptom Assessment Scale and a depression screen. This information will be given to the health care practitioner before the patient visit.
* Patients facing a treatment decision will receive a Patient Information Program link (or paper for those unable to work on the iPad) to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy. This will then give transition "prompts" to encourage thinking about advance directives, durable power of medical attorney, use of hospice, and doing a life review.
* We will also offer a hospice information visit when patient has - in the projection of the team or treating physician - 3 to 6 months to live.
* The palliative care team will meet at least monthly with each of the enrolled patients.
* Participants will be followed for as long as he or she is alive before receiving hospice care.

Eligibility Criteria:
Inclusion Criteria:

* All patients with metastatic pancreas cancer will be eligible, ages 18 and above.
* There is no limit to the amount of prior therapy for metastatic disease.
* Ability to understand and the willingness to sign a written informed consent document and to answer a questionnaire.
* English speakers.

Exclusion Criteria:

* Patients who have tumors other than metastatic pancreas cancer.
* Patients who actively decline participation or who are judged to be in distress before the interview.
* Patients who are pregnant.
Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D

The purpose of this study is to describe the effect of anti-D on symptoms and platelet count in children suffering from unexplainable low platelet counts, when anti-D is administered as an injection under the skin. The hypothesis is that the injection with anti-D under the skin is as effective as anti-D given in a vein.

Background:

Idiopathic thrombocytopenic purpura (ITP) in children is considered a benign hematological disease. The incidence is approximately 50 cases a year in Denmark. Approximately 25 % will experience chronic disease. Follow up and treatment of these patients is not centralized.

The drug of choice is intravenous IgG (IVIG) for treatment of ITP. The side effects are flu-like symptoms, and in rare cases aseptic meningitis. Another option is intravenous anti-D, if the child is rhesus positive. Anti-D is primarily used in North America. The effect of Anti-D is comparable with IVIG when considering the time it takes to bring the platelet count above 50,000/μL. Anti-D also causes flu-like symptoms. Establishing an i.v. access is a disadvantage to both IVIG and anti-D. For both treatments mechanism of action is not finally described.

Subcutaneous IgG substitution therapy is used for patients suffering from agammaglobulinaemia. It is therefore known, that immunoglobulin uptake is possible after subcutaneous administration. Subcutaneous anti-D has been tried in few patients suffering from chronic thrombocytopenia with positive results.

IVIG treatment is expensive compared to anti-D. Treatment of a 20 kg child costs approximately 17,000 Dkr for IVIG and 2,500 Dkr. for anti-D.

Hypothesis:

* Subcutaneous administered anti-D is as effective as IVIG/i.v. anti-D;
* Subcutaneous administered anti-D has fewer less severe side effects than IVIG/i.v. anti-D.

Purpose:

* To document the effect of subcutaneous anti-D;
* Describe complications;
* Describe aspects of the mechanism of action.

Material and Methods:

Children are eligible if admitted to a pediatric department in Denmark for diagnosis, observation or treatment of acute or chronic ITP. Examination and diagnostic work up is similar throughout the country, but not identical. No specific tests are required for diagnosis. If treatment is indicated rhesus positive children are treated with subcutaneous anti-D. Rhesus negative children are treated according to local guidelines. Specified follow-up on all children is mandatory. For research purposes one blood sample form all children is collected, and from children, who receive medical treatment, several blood samples are collected. Analysis for changes in immunological signaling peptides will be performed with special attention to the mechanism of action of anti-D.

Eligibility Criteria:
Inclusion Criteria:

* Idiopathic thrombocytopenic purpura (ITP)
Transthoracic Needle Biopsy Using 3D Printed Navigational Template: A Phase I Feasibility Trial

This study evaluates the feasibility of three-dimensional printed template in transthoracic pulmonary nodule biospy. Investigator planned to include 20 patients with lung nodule biopsy schedule to receive template-guided transthoracic needle aspiration.

In previous study,a navigational template has been created to simplify the procedure of preoperative lung nodule localization. It was reported that localizer deviation was 10(0-20)mm.In this trial,Investigator explores the utility of this navigational template in transthoracic lung nodule biopsy.

Eligibility Criteria:
Inclusion Criteria:

CT confirmed peripheral lung nodule; Nodule size larger than or equal to 3 cm; ECOG Performance Status 0-2 ; Informed consent.

Exclusion Criteria:

Nodule located in the scapula region wherein biopsy needle is impeded; Nodule within 3 cm above diaphragmatic dome.
Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control

This proposal seeks to gather continuous blood glucose and physical activity data from individuals with and without diabetes.

This proposal seeks to gather continuous blood glucose and physical activity data from individuals with and without diabetes who are physically active and exercising for health benefits. The investigators hypothesize that insulin requirements will be inversely related to intensity of activity and an algorithm will be able to detect physical activity and automatically adjust insulin doses. Once such an algorithm has been determined for an individual, it can be applied to future similar situations, but ideally the algorithm will be dynamically refined based on closed-loop feedback information.

Eligibility Criteria:
Inclusion Criteria:

* Inclusion criteria for subjects with diabetes
* Type 1 diabetes or insulin requiring type 2 diabetes for at least 1 year
* Use insulin to control diabetes
* Physically active (regularly work out, swim, run, walk, bike, etc.)
* Free of major micro- and macrovascular complications of diabetes
* 18-75 years of age
* A1C \< 9.0% Inclusion criteria for subjects without diabetes
* No evidence of diabetes and physically active

Exclusion Criteria:

* unwilling to perform repeated glucose checks or take insulin as instructed
* abnormal thyroid function, kidney function, liver function
* pregnancy
Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate

dose-finding study to assess the optimal dose of glycopyrrolate daily dose on top of BDP/FF in COPD patients.

A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED, 4-WAY CROSS-OVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A FREE COMBINATION OF 3 DOSES OF GLYCOPYRROLATE WITH FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL (FOSTER®) IN A METERED DOSE INHALER FOR THE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Eligibility Criteria:
Inclusion Criteria:

* COPD over 40 years of age (30 to 60% post-bronchodilator FEV1 predictive value)
* Patients under Double
* Patients under triple therapy (for 1 Mo prior Screening)

Exclusion Criteria:

* Pregnant or lactating women
* Patients experiencing a COPD exacerbation requiring use of systemic steroids and/or antibiotics, hospitalization
* concommitant diseases impacting feasibility or safety
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea

This clinical study is to determine the optimum dose of PAC-14028 cream in a therapeutic confirmatory clinical study by evaluating the safety and therapeutic equivalence of PAC-14028 cream 0.1%, 0.3% and 1.0% in patients with rosacea.


Eligibility Criteria:
Inclusion Criteria:

* Male and female patients aged 19 - 70 years old
* Among the patients diagnosed with erythematotelangiectatic and papulopustular rosacea in accordance with the diagnostic criteria of the National Rosacea Society Expert Committee
* Subjects with rosacea scored 2 or more according to the Investigator Global Assessment (IGA) at screening

Exclusion Criteria:

* Those who can't be diagnosed or assessed for rosacea due to the presence of trauma, tattoo, scar, excessive hairs on the facial region
* Those who have received a facial laser treatment within 6 weeks
* Those who have been administered with oral retinoid or therapeutic vitamin A within 6 months
* Those who have received a hormonal treatment such as estrogen within 3 months
* Those who have been administered with systemic antibiotics or systemic steroid formulation within 4 weeks
* Those who have been administered with local retinoid, local steroid and local antibiotics and local medication for the treatment of rosacea on face within 4 weeks
* Those who have a history of blood disorder that can have a serious effect on the clinical study
* Women who are pregnant, lactating or who plan to be pregnant during the clinical study period or women of childbearing potential who do not use available contraceptive methods
Contraception in Normal and Subnormal Men

Volunteers with normal and subnormal semen parameters receive a hormonal male contraceptive in order to investigate whether there are differences between normal and subnormal men in terms of suppressibility, rate of azoospermia and reversibility of suppression of spermatogenesis.

Volunteers with normal and subnormal semen parameters receive a hormonal male contraceptive in order to investigate whether there are differences between normal and subnormal men in terms of suppressibility, rate of azoospermia and reversibility of suppression of spermatogenesis. Twenty-five men will be recruited for each group. They will be exposed to hormonal male contraception for six months.

Eligibility Criteria:
Inclusion Criteria:

* Volunteers with normal and subnormal semen parameters
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.

This is a prospective cohort study that examines the impact of myopenia on chemotherapy toxicity in overall survival (OS) in older adults with newly diagnosed metastatic colorectal cancer (CRC) receiving 5-Fluouracil (5FU)systemic chemotherapy. The study also explores the mediating influence of genetic variation in the association between myopenia and chemotherapy toxicity.

Eligibility Criteria:
Inclusion Criteria:

* Newly diagnosed metastatic CRC or newly recognized metastatic recurrence of CRC \>= to 3 months (12 weeks) from completion of treatment of non-metastatic CRC.
* Planning to or recently started to undergo undergo immunotherapy and/or 5-FU based chemotherapy as a first line of treatment. 5-FU chemotherapy can be 5-FU alone or in combination with oxaliplatin and/or irinotecan +/- immunotherapy. Capecitabine is also acceptable.
* Estimated life expectancy \>= 6 months.
* Patients must be able to comprehend English or Spanish (for questionnaire completion).
* Ability to understand and the willingness to sign a written informed consent document.
* Patient eligibility is not dependent on BMI or weight. Patients with a significant (+- \> 10%) body weight change in the previous 12 months are eligible for this study.

Exclusion Criteria:

* Patients enrolled on hospice.
* Prior systemic chemotherapy for metastatic colorectal cancer (ok if adjuvant chemotherapy completed \>= 3 months (12 weeks) prior to this disease disease recurrence and treatment).
* Patients may not be receiving any other investigational agents.
* No untreated brain metastases. Patients with treated brain metastases are eligible.
* Patients on or planned to undergo radiation therapy in near future.
NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder

The purpose of this study is to determine the efficacy and tolerance of 2 dosages (750 versus 500 units) of the Dysport type A botulinic toxin for patient suffering from neurogenic urinary incontinence by an overactive bladder and the failure of anticholinergic drugs.


Eligibility Criteria:
Inclusion Criteria:

* Neurogenic urinary incontinence with urodynamic overactivity resistant to anticholinergic

Exclusion Criteria:

* Pregnancy
* Bladder cancer
* Symptomatic urinary infection
Characterization of Acute Myocardial Damage With Spectral Computed Tomography. (CADAMI-SPECTRAL)

Clinical management of patients with chest pain and elevation of biomarkers of myocardial injury require an accurate diagnosis. Until now, cardiac magnetic resonance imaging (cMRI) is the gold standard for the diagnosis among myocarditis, stress cardiomyopathy, or inapparent ischemic damage. The development of spectral CT has opened up the possibility of characterizing the coronary anatomy and the myocardium in a single procedure. Our aim is to assess the diagnostic ability of differential patterns in first- pass perfusion and delayed iodine enhancement obtained by spectral CT in patients with acute myocardial injury. This study is designed as a prospective multicenter observational study with diagnostic intervention in 150 patients admitted with clinical indication of a cMRI due to suspicion of myocardial infarction with normal coronary arteries (MINOCA), myocarditis or stress cardiomyopathy who will undergo a CT study with double detector technology in two reference centers. A control group (n=150) with an indication for cardiac CT for another cause without coronary or structural heart disease will be included. The iodine maps obtained by spectral CT will be compared with the findings obtained with cMRI, both with conventional techniques and with artificial intelligence algorithms (deep learning). A year follow-up of the cohort will be carried out to assess whether the findings derived from the CT in this group of patients provide prognostic information


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 year.
* Hospital admission due to chest pain and acute myocardial injury.
* Clinical indication for cardiac MRI (CMR) due to suspected acute myocardial infarction with coronary angiography showing no significant lesions (\<50%) (MINOCA), acute myocarditis, or stress-induced cardiomyopathy.
* Signed informed consent.

Exclusion Criteria:

* Contraindications to undergo cardiac MRI and CT with administration of gadolinium and/or iodine-based contrast, respectively.
* Pre-existing cardiomyopathy.
* Pre-existing chronic ischemic heart disease.
* Invasive coronary angiography showing coronary lesions ≥50%.
Intraoperative Transfusion Practice in Children

The purpose of this study is to examine factors, impact and outcome on perioperative blood transfusion for pediatric patients.


Eligibility Criteria:
Inclusion Criteria:

* Operation
* Anaesthesia
* Transfusion (pRBC, plasma or platelets)

Exclusion Criteria:

* No